4
Changes in Ownership
Candel Therapeutics, Inc. Filed Acc 0001873905-26-000002
Chief Executive Officer sold 280,245 shares at an average $11.28 ($3,160,783)
- Chief Executive Officer acquired 125,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter Chief Executive Officer | 2026-09-10 | Option exercise 10b5-1 | +125,000 | $1.55 | $193,750 | 393,566 | D |
| Tak Paul Peter Chief Executive Officer | 2026-09-10 | Sale 10b5-1 | −220,866 | $11.50 | $2,539,893 | 172,700 | D |
| Tak Paul Peter Chief Executive Officer | 2026-09-11 | Sale 10b5-1 | −59,379 | $10.46 | $620,891 | 113,321 | D |
| Derivatives | |||||||
| Tak Paul Peter Chief Executive Officer | 2026-09-10 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −125,000 | 1,638,968 | D | ||
| Open-market sales · 280,245 sh · avg $11.28 · $3,160,783 | |||||||
Loading xslF345X06/ownership.xml…